The result is notable because these patients had already progressed after both immunotherapy and chemotherapy, leaving relatively few effective options. A meaningful overall-survival benefit at that stage can make a drug clinically important if regulators confirm the data.

BioNTech↗ reported that gotistobart significantly improved overall survival in the PRESERVE-003 Phase 3 trial for previously treated squamous non-small cell lung cancer.